Somatropin intranasal - Critical Pharmaceuticals
Alternative Names: CP-024Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Critical Pharmaceuticals
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for phase-I development in Somatotropin-deficiency in United Kingdom (Intranasal, Spray)
- 14 Mar 2016 Phase I development is ongoing in the UK
- 21 Nov 2013 Phase-I clinical trials in Somatotropin deficiency in United Kingdom (Intranasal)